Xenon Pharma

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with neurological disorders, particularly epilepsy and depression. The company leverages its proprietary Extreme Genetics discovery platform to identify targets based on human genetic data and rare phenotypes. Its lead candidate, XEN1101, is a potent potassium channel opener currently in Phase 3 clinical trials for focal onset seizures and Phase 2 for major depressive disorder. Xenon also maintains a strategic partnership with Neurocrine Biosciences to advance NBI-921352, a selective sodium channel inhibitor for pediatric and adult epilepsy.